Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases
Open Access
- 19 August 2008
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (5) , 741-749
Abstract
New therapies are needed that target breast cancer metastases. In previous studies, we have shown that vaccination with pcDNA3.1-Mage-b DNA vaccine is effective against breast cancer metastases. In the study presented here, we have further enhanced the efficacy of Mage-b vaccination through the improved delivery of the vaccine using recombinant Listeria monocytogenes (LM). Three overlapping fragments of Mage-b as well as the complete protein-encoding region of Mage-b have been expressed as a fusion protein with a truncated non-cytolytic form of listeriolysin O (LLO) in recombinant LM. These different Mage-b vaccine strains were preventively tested for their efficacy against breast cancer metastases in a syngeneic mouse tumour model 4T1. The LM-LLO-Mage-b/2nd, expressing position 311–660 of the cDNA of Mage-b, was the most effective vaccine strain against metastases in the 4T1 mouse breast tumour model. Vaccination with LM-LLO-Mage-b/2nd dramatically reduced the number of metastases by 96% compared with the saline group and by 88% compared with the vector control group (LM-LLO), and this correlated with strong Mage-b-specific CD8 T-cell responses in the spleen, after restimulation with Mage-b. However, no effect of LM-LLO-Mage-b/2nd was observed on 4T1 primary tumours, which may be the result of a complete absence of Mage-b-specific immune responses in the draining lymph nodes. Vaccination with LM-LLO-Mage-b/2nd could be an excellent follow-up after removal of the primary tumour, to eliminate metastases and residual tumour cells.Keywords
This publication has 45 references indexed in Scilit:
- Cancer vaccines in old ageExperimental Gerontology, 2007
- Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T CellsJournal of Clinical Oncology, 2005
- Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanomaInternational Journal of Cancer, 2005
- Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapyBreast Cancer Research and Treatment, 2005
- Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer PatientsMolecular & Cellular Proteomics, 2005
- Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigenJournal of Experimental Medicine, 2005
- ListeriaPathogenesis and Molecular Virulence DeterminantsClinical Microbiology Reviews, 2001
- Epidemiology of Breast Cancer in Older WomenDrugs & Aging, 2001
- Estimates of the Lifetime Direct Costs of Treatment for Metastatic Breast CancerValue in Health, 2000
- Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced MacrophagesScience, 1993